Clinical Trials
87 trialsA Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
LEAP-005
Merck Sharp & Dohme LLC
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
NeoSACT
Guangdong Provincial People's Hospital
RADIOLA
SOLTI Breast Cancer Research Group
KEYLYNK-009
Merck Sharp & Dohme LLC
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
OPALESCENCE
Institut Cancerologie de l'Ouest
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
PRIMED
MedSIR
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
ROLo
Royal Marsden NHS Foundation Trust
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Beni-Suef University
KEYVIBE-005
Merck Sharp & Dohme LLC
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
Sun Yat-sen University
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
PAKT
Queen Mary University of London
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Georgetown University
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Yale University
STOMP
The Methodist Hospital Research Institute
ALICE
Oslo University Hospital
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
US Oncology Research
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
Henan Cancer Hospital
PATHFINDER
MedSIR
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
HiberCell, Inc.
ATRACTIB
MedSIR
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CytomX Therapeutics
Study of Tremelimumab in Patients With Advanced Solid Tumors
AstraZeneca
YAPPETIZER
Mario Negri Institute for Pharmacological Research
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Case Comprehensive Cancer Center
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Baylor Research Institute
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
AstraZeneca
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Stanford University
EITHICS
Institut Cancerologie de l'Ouest
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Novartis
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Calithera Biosciences, Inc
DORA
Duke University